about
The arsenal of pathogens and antivirulence therapeutic strategies for disarming themAdhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 piliAn Overview of Two-Component Signal Transduction Systems Implicated in Extra-Intestinal Pathogenic E. coli InfectionsIdentification of a High-Affinity Pyruvate Receptor in Escherichia coli.QseC-mediated dephosphorylation of QseB is required for expression of genes associated with virulence in uropathogenic Escherichia coli.Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors.Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.Intrinsic curvature associated with the coordinately regulated anthrax toxin gene promoters.Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infectionThe alternative sigma factor sigmaH is required for toxin gene expression by Bacillus anthracisPeptidomimetic Small Molecules Disrupt Type IV Secretion System Activity in Diverse Bacterial Pathogens.Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.Molecular blueprint of uropathogenic Escherichia coli virulence provides clues toward the development of anti-virulence therapeutics.A central metabolic circuit controlled by QseC in pathogenic Escherichia coli.Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.Metabolic Requirements of Escherichia coli in Intracellular Bacterial Communities during Urinary Tract Infection PathogenesisEscherichia coli biofilms have an organized and complex extracellular matrix structureStrong cross-system interactions drive the activation of the QseB response regulator in the absence of its cognate sensor.Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli.The yin-yang driving urinary tract infection and how proteomics can enhance research, diagnostics, and treatment.The Histidine Residue of QseC Is Required for Canonical Signaling between QseB and PmrB in Uropathogenic Escherichia coli.Characterization of blue light irradiation effects on pathogenic and nonpathogenic Escherichia coli.What does it take to stick around? Molecular insights into biofilm formation by uropathogenic Escherichia coli.Signaling by two-component system noncognate partners promotes intrinsic tolerance to polymyxin B in uropathogenic Escherichia coli.Biofilm Formation by Uropathogenic Escherichia coli Is Favored under Oxygen Conditions That Mimic the Bladder Environment.Evidence of Cross-Regulation in Two Closely Related Pyruvate-Sensing Systems in Uropathogenic Escherichia coli.Options and Limitations in Clinical Investigation of Bacterial Biofilms.Antitoxins: therapy for stressed bacteria.A Dual Role for the Bacillus anthracis Master Virulence Regulator AtxA: Control of Sporulation and Anthrax Toxin Production.Respiratory Heterogeneity Shapes Biofilm Formation and Host Colonization in Uropathogenic Escherichia coliDefining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical OpportunitiesInvasion of vaginal epithelial cells by uropathogenic Escherichia coli
P50
Q26745604-A3AE80A2-9832-415E-9F6A-26FB6FDEDE3EQ27321012-17F967F3-27F8-4DD9-898E-1A70581A05DFQ33650044-753FD10B-35DB-44ED-B47F-3DC1D14CACC4Q33684397-781152A9-FCCF-4101-922C-28EB7D7485F9Q34235966-703B6AEE-C7CB-4A65-80BF-A63D4EC8F398Q34415785-B4EB46BC-9D05-4305-A356-0EBADEBE5F5BQ34440901-4E7572DF-C7D8-4432-B22B-4E770BF9AA4FQ34476031-10BE99F8-E510-47B1-84F4-C9E5499C89A0Q35134655-0809E867-5C43-430E-8675-752B2365231CQ35759352-D6EC4DC0-85D1-42F1-84AC-94A0D9904323Q36000469-6749FF9F-6BEE-4F75-9E18-E0C2E08A4671Q36211104-69E852B6-B472-4F97-AE55-24CC00178D8CQ36535780-C6339B73-DDFB-4782-905C-35664E1B2A9FQ36814083-9034695B-978A-4934-A489-C6EBE24DC307Q36933039-275E640A-B560-4368-89B3-4A783EDD76E9Q37123051-D5913132-0B6E-42E4-A353-25369EA87479Q37174545-AAC4822A-335F-4C2B-989B-3146E4238535Q37236417-6BB5864C-14B3-4CE2-B0B3-6EBB151BF59BQ37547007-9445DC0C-6EB3-4357-8C7B-76F367AF2A8BQ38563209-D2D37E62-1448-4D98-9C39-EDE414145401Q40257211-B9EAC935-3154-4DCC-9F70-05DF996380A6Q40282417-5C2A7366-BE5A-4F4B-8B60-59AA2D958B31Q42325472-AE3BDAB5-D8B2-4434-A5CD-835294301778Q47099892-DB3208B9-A825-479B-9740-742326197E27Q47150911-4EA1575B-7F4F-4B13-A005-B34FA4314737Q48157607-37DDCC6F-77CC-401F-B555-74C0C316F5ECQ52331891-BD333470-B816-40C9-B085-4F858E0AD489Q54361187-C852A533-90C0-4316-BC70-3A3E0B0A13FDQ54981524-6AD01B9E-A2F2-4B25-9F4D-1A4F8B0D0CBEQ64086002-26F6FEFD-D92E-4497-86D2-1C2854FC0C1DQ91639970-C2C6B4E4-4CE9-4EA6-ADF6-04A4310F1B33Q96136152-D40CDFE2-ABCD-4C4B-B0B7-4005DDA2123B
P50
description
investigador
@es
pathologist
@en
wetenschapper
@nl
name
Maria Hadjifrangiskou
@en
Maria Hadjifrangiskou
@nl
type
label
Maria Hadjifrangiskou
@en
Maria Hadjifrangiskou
@nl
prefLabel
Maria Hadjifrangiskou
@en
Maria Hadjifrangiskou
@nl
P101
P1416
P21
P31
P496
0000-0003-4249-8997